Viral Hepatitis Vaccines
Hepatitis, Viral, Human
Hepatitis A
Hepatitis B
Hepatitis C
Vaccines
Hepatitis B virus
Hepatitis B, Chronic
Hepatitis B Surface Antigens
Hepatitis C, Chronic
Hepatitis B Vaccines
Hepatitis, Chronic
Hepatitis A Vaccines
Vaccines, Inactivated
Hepatitis A virus
Hepatitis B Antibodies
Hepatitis B Antigens
Viral Vaccines
Hepatitis Viruses
Hepatitis Antibodies
Vaccines, Synthetic
Vaccines, DNA
Hepatitis E
Hepatitis A Antibodies
Bacterial Vaccines
Hepatitis D
Hepacivirus
Hepatitis E virus
Hepatitis C Antibodies
Hepatitis B Core Antigens
Hepatitis A Virus, Human
Hepatovirus
Liver Cirrhosis
AIDS Vaccines
Hepatitis B e Antigens
Vaccination
Vaccines, Subunit
Vaccines, Conjugate
Jaundice
Hepatitis, Autoimmune
Hepatitis Delta Virus
Alanine Transaminase
Antiviral Agents
Liver
Malaria Vaccines
Carcinoma, Hepatocellular
Papillomavirus Vaccines
Murine hepatitis virus
Interferon-alpha
Liver Function Tests
Meningococcal Vaccines
Aspartate Aminotransferases
Hepatitis, Alcoholic
Ribavirin
Seroepidemiologic Studies
Measles Vaccine
Haemophilus Vaccines
Poliovirus Vaccine, Inactivated
Pertussis Vaccine
BCG Vaccine
Rabies Vaccines
Hepatitis B Virus, Woodchuck
Cholera Vaccines
Hepatitis C Antigens
Immunization Schedule
Hepatic Encephalopathy
Prevalence
Hepatitis D, Chronic
Marmota
Liver Failure, Acute
Typhoid-Paratyphoid Vaccines
Diphtheria-Tetanus-Pertussis Vaccine
Smallpox Vaccine
Molecular Sequence Data
Immunization, Secondary
Drug-Induced Liver Injury
Chickenpox Vaccine
Liver Transplantation
HIV Infections
Adjuvants, Immunologic
Mumps Vaccine
Chronic Disease
Hepatitis A Antigens
Virus Replication
Hepatitis Antigens
Immunoglobulin G
Carrier State
Enzyme-Linked Immunosorbent Assay
Hepatocytes
Risk Factors
Egypt
Immunization
Hepatitis B Virus, Duck
Lamivudine
Viral Nonstructural Proteins
Viral Load
Liver Cirrhosis, Alcoholic
Vaccines, Virosome
Dengue Vaccines
Genotype
Polyethylene Glycols
Liver Failure
Pan troglodytes
Poliovirus Vaccine, Oral
Immunoglobulin M
Retrospective Studies
Yellow Fever Vaccine
Immunization Programs
Plague Vaccine
Incidence
Fungal Vaccines
Treatment Outcome
Vaccines, Virus-Like Particle
Biopsy
Fatty Liver
Rubella Vaccine
Population Surveillance
Base Sequence
Biological Markers
Viral Core Proteins
Vaccines, Acellular
Disease Outbreaks
Antibodies, Neutralizing
SAIDS Vaccines
Salmonella Vaccines
Polymerase Chain Reaction
Injections, Intramuscular
Military Medicine
Influenza, Human
Liver Diseases, Alcoholic
Drug Therapy, Combination
Diphtheria-Tetanus-acellular Pertussis Vaccines
Viral Envelope Proteins
Interferons
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. (1/271)
Hybrids of tobacco mosaic virus (TMV) were constructed with the use of fusion to the coat protein peptides of 10 or 15 amino acids, containing the 5B19 epitope from the spike protein of murine hepatitis virus (MHV) and giving rise to TMV-5B19 and TMV-5B19L, respectively. The TMV hybrids were propagated in tobacco plants, and the virus particles were purified. Immunogold labeling, with the use of the monoclonal MAb5B19 antibody, showed specific decoration of hybrid TMV particles, confirming the expression and display of the MHV epitope on the surface of the TMV. Mice were immunized with purified hybrid viruses after several regimens of immunization. Mice that received TMV-5B19L intranasally developed serum IgG and IgA specific for the 5B19 epitope and for the TMV coat protein. Hybrid TMV-5B19, administered by subcutaneous injections, elicited high titers of serum IgG that was specific for the 5B19 epitope and for coat protein, but IgA that was specific against 5B19 was not observed. Mice that were immunized with hybrid virus by subcutaneous or intranasal routes of administration survived challenge with a lethal dose (10 x LD50) of MHV strain JHM, whereas mice administered wild-type TMV died 10 d post challenge. Furthermore, there was a positive correlation between the dose of administered immunogen and protection against MHV infection. These studies show that TMV can be an effective vaccine delivery vehicle for parenteral and mucosal immunization and for protection from challenge with viral infection. (+info)Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. (2/271)
Interactive glycoproteins present on the surface of viral particles represent the main target of neutralizing antibodies. The ability of DNA vaccination to induce antibodies directed at such structures was investigated by using eight different expression plasmids engineered either to favor or to prevent interaction between the hepatitis C virus (HCV) envelope glycoproteins E1 and E2. Independently of the injection route (intramuscular or intraepidermal), plasmids expressing antigens capable of forming heterodimers presumed to be the prebudding form of the HCV envelope protein complex failed to induce any significant, stable antibodies following injection in mice. In sharp contrast, high titers of antibodies directed at both conformational and linear determinants were induced by using plasmids expressing severely truncated antigens that have lost the ability to form native complexes. In addition, only a truncated form of E2 induced antibodies reacting against the hypervariable region 1 of E2 (specifically with the C-terminal part of it) known to contain a neutralization site. When injected intraepidermally into small primates, the truncated E2-encoding plasmid induced antibodies able to neutralize in vitro the binding of a purified E2 protein onto susceptible cells. Because such antibodies have been associated with viral clearance in both humans and chimpanzees, these findings may have important implications for the development of protective immunity against HCV. (+info)Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). (3/271)
Routine vaccination of children is the most effective way to reduce hepatitis A incidence nationwide over time. Since licensure of hepatitis A vaccine in 1995, this strategy has been implemented incrementally, starting with the recommendation of the Advisory Committee on Immunization Practices (ACIP) in 1996 to vaccinate children living in communities with the highest rates of infection and disease. These updated recommendations represent the next phase of this hepatitis A immunization strategy. Vaccination of children living in states and communities with consistently elevated rates of hepatitis A will provide protection from disease and is expected to reduce the overall incidence of hepatitis A. This report updates the ACIP's 1996 recommendations on the prevention of hepatitis A through immunization (MMWR 1996;45:[No. RR-151) and includes a) new data about the epidemiology of hepatitis A; b) recent findings about the effectiveness of community-based hepatitis A vaccination programs; and c) recommendations for the routine vaccination of children in states, counties, and communities with rates that are twice the 1987-1997 national average or greater (i.e., > or = 20 cases per 100,000 population) and consideration of routine vaccination of children in states, counties, and communities with rates exceeding the 1987-1997 national average (i.e., > or = 10 but <20 cases per 100,000 population). Unchanged in this report are previous recommendations regarding the vaccination of persons in groups at increased risk for hepatitis A or its adverse consequences and recommendations regarding the use of immune globulin for protection against hepatitis A. (+info)Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. (4/271)
Organ transplant recipients with chronic hepatitis B or hepatitis C virus infection may be at increased risk of fulminant hepatitis A. Liver transplant (LTX) recipients, renal transplant (RTX) recipients, and healthy controls received 2 doses of hepatitis A vaccine 6 months apart. Anti-hepatitis A virus (anti-HAV) seroconversion after the primary dose occurred in 41% of the LTX patients, 24% of the RTX patients, and 90% of the controls. After the booster dose, the respective rates were 97%, 72%, and 100% (P<.001). RTX patients also had significantly lower geometric mean titers (GMTs) of anti-HAV than LTX patients and controls. In the RTX group, the seroconversion rate and GMT were inversely associated with the number of immunosuppressive drugs received by the patients. The vaccine was well tolerated. Hepatitis A vaccine can be recommended to LTX and RTX patients, but the patients should receive a full course of 2 doses before imminent exposure. (+info)Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. (5/271)
A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers >/=11 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference. (+info)Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. (6/271)
BACKGROUND: Hepatitis B (HBV)-infected patients have a higher morbidity and mortality when super-infected by hepatitis A (HAV). AIM: To evaluate the immunogenicity and safety of a commercial inactivated HAV vaccine in Chinese patients with chronic HBV infection. METHODS: Sixty-five HBV-infected patients (30 carriers, 22 chronic hepatitis, 13 cirrhosis), who were seronegative for HAV, received a dose of 1440 ELISA units of HAV vaccine at weeks 0 and 24. Twenty-eight healthy individuals aged 18-57 years, who were seronegative for both HBV and HAV infection, also received the same vaccination regimen. Seroconversion was defined as an anti-HAV titre >/= 33 mIU/mL. RESULTS: The seroconversion rates for the HBV-infected patients at weeks 2, 4 and 24 were 72, 91 and 80%, respectively. The corresponding geometric mean titres (GMTs) were 103, 311 and 123 mIU/mL. In the healthy control group the seroconversion rates were 86, 93 and 89% at weeks 2, 4 and 24. The corresponding GMTs were 112, 158 and 250 mIU/mL. There was no difference in the seroconversion rates between the two groups, but healthy controls had a significantly higher GMT at week 24 (P=0.04). Side-effects were more common in HBV patients. CONCLUSION: The HAV vaccine is equally efficacious in patients with chronic HBV infection. (+info)Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. (7/271)
DNA-based immunizations have been used to elicit cellular immunity to hepatitis C virus (HCV) proteins in mice. Mice were immunized by intramuscular or intradermal injections of plasmid DNA derived from a near-full-length HCV genotype 1b genomic clone (pRC/B2) or individual genomic clones. These immunizations induced cytotoxic T lymphocytes (CTLs), as revealed in standard chromium-release assays that used syngeneic peptide-pulsed or transfected target cells. These assays identified four CTL epitopes within the capsid, E1, and E2 regions of the polyprotein sequence of HCV genotype 1a that were cross-reactive with HCV genotype 1b. Additionally, CTLs derived from mice immunized with either NS3 or NS5 specifically lysed target cells sensitized to either the genotype 1a or 1b gene products. Nucleic acid immunizations also generated humoral immunity to HCV proteins, as detected by anti-HCV reactivity to NS3 and capsid in ELISAs and immunoblot assays. (+info)Prevalence of hepatitis B, D and C virus infections among children and pregnant women in Moldova: additional evidence supporting the need for routine hepatitis B vaccination of infants. (8/271)
Rates of acute hepatitis B are high in Moldova, but the prevalence of chronic infection is unknown. In 1994, we surveyed children and pregnant women, collected demographic information, and drew blood for laboratory testing. Among the 439 children (mean age, 5 years), the prevalence of antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were 17.1 and 6.8%, respectively. Among the 1098 pregnant women (mean age, 26 years), 52.4% were anti-HBc-positive and 9.7% were HBsAg-positive. Of the HBsAg-positive pregnant women, 35.6% were hepatitis B e antigen (HBeAg) positive and 18.3% had antibodies to hepatitis D virus. The prevalence of antibody to hepatitis C virus was 1.4% in children and 2.3% in pregnant women. The high HBeAg prevalence among HBsAg-positive pregnant women and the high anti-HBc prevalence among children indicate that both perinatal and early childhood transmission contribute to the high hepatitis B virus endemicity in Moldova. (+info)Note: This definition may have some variations in different contexts and medical fields.
Hepatitis A is typically spread through contaminated food and water or through close contact with someone who has the infection. The virus can also be spread through sexual contact or sharing of needles.
Symptoms of hepatitis A usually appear two to six weeks after exposure and can last for several weeks or months. In some cases, the infection can lead to complications such as liver failure, which can be life-threatening.
There is a vaccine available for hepatitis A, which is recommended for individuals traveling to areas where the virus is common, people who engage in high-risk behaviors, and those with chronic liver disease. Treatment for hepatitis A typically focuses on relieving symptoms and supporting the liver as it recovers. In severe cases, hospitalization may be necessary.
Preventive measures to reduce the risk of hepatitis A infection include maintaining good hygiene practices, such as washing hands frequently, especially before eating or preparing food; avoiding consumption of raw or undercooked shellfish, particularly oysters; and avoiding close contact with people who have the infection.
The symptoms of hepatitis B can range from mild to severe and may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, joint pain, and jaundice (yellowing of the skin and eyes). In some cases, hepatitis B can be asymptomatic, meaning that individuals may not experience any symptoms at all.
Hepatitis B is diagnosed through blood tests that detect the presence of HBV antigens or antibodies in the body. Treatment for acute hepatitis B typically involves rest, hydration, and medication to manage symptoms, while chronic hepatitis B may require ongoing therapy with antiviral drugs to suppress the virus and prevent liver damage.
Preventive measures for hepatitis B include vaccination, which is recommended for individuals at high risk of infection, such as healthcare workers, sexually active individuals, and those traveling to areas where HBV is common. In addition, safe sex practices, avoiding sharing of needles or other bodily fluids, and proper sterilization of medical equipment can help reduce the risk of transmission.
Overall, hepatitis B is a serious infection that can have long-term consequences for liver health, and it is important to take preventive measures and seek medical attention if symptoms persist or worsen over time.
There are several types of hepatitis C, including genotype 1, which is the most common and accounts for approximately 70% of cases in the United States. Other genotypes include 2, 3, 4, 5, and 6. The symptoms of hepatitis C can range from mild to severe and may include fatigue, fever, loss of appetite, nausea, vomiting, joint pain, jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching all over the body. Some people with hepatitis C may not experience any symptoms at all.
Hepatitis C is diagnosed through a combination of blood tests that detect the presence of antibodies against HCV or the virus itself. Treatment typically involves a combination of medications, including interferon and ribavirin, which can cure the infection but may have side effects such as fatigue, nausea, and depression. In recent years, new drugs known as direct-acting antivirals (DAAs) have become available, which can cure the infection with fewer side effects and in a shorter period of time.
Prevention measures for hepatitis C include avoiding sharing needles or other drug paraphernalia, using condoms to prevent sexual transmission, and ensuring that any tattoos or piercings are performed with sterilized equipment. Vaccines are also available for people who are at high risk of contracting the virus, such as healthcare workers and individuals who engage in high-risk behaviors.
Overall, hepatitis C is a serious and common liver disease that can lead to significant health complications if left untreated. Fortunately, with advances in medical technology and treatment options, it is possible to manage and cure the virus with proper care and attention.
A persistent infection with the hepatitis B virus (HBV) that can lead to liver cirrhosis and hepatocellular carcinoma. HBV is a bloodborne pathogen and can be spread through contact with infected blood, sexual contact, or vertical transmission from mother to child during childbirth.
Chronic hepatitis B is characterized by the presence of HBsAg in the blood for more than 6 months, indicating that the virus is still present in the liver. The disease can be asymptomatic or symptomatic, with symptoms such as fatigue, malaise, loss of appetite, nausea, vomiting, joint pain, and jaundice.
Chronic hepatitis B is diagnosed through serological tests such as HBsAg, anti-HBc, and HBV DNA. Treatment options include interferon alpha and nucleos(t)ide analogues, which can slow the progression of the disease but do not cure it.
Prevention strategies for chronic hepatitis B include vaccination with hepatitis B vaccine, which is effective in preventing acute and chronic HBV infection, as well as avoidance of risky behaviors such as unprotected sex and sharing of needles.
The symptoms of chronic hepatitis C may be mild or absent, but some people experience fatigue, joint pain, muscle aches, nausea, loss of appetite, and jaundice (yellowing of the skin and eyes).
Chronic hepatitis C is usually diagnosed through blood tests that detect the presence of antibodies against HCV or the virus itself. Imaging tests such as ultrasound and liver biopsy may also be performed to assess the extent of liver damage.
Treatment for chronic hepatitis C typically involves a combination of medications, including interferon and ribavirin, which can help clear the virus from the body. In severe cases, a liver transplant may be necessary. Prevention of the spread of HCV includes avoiding sharing of needles or other sharp objects, practicing safe sex, and getting tested for the virus before donating blood or organs.
See also: Hepatitis C; Liver; Virus
There are several types of hepatitis, including:
1. Hepatitis A: This type is caused by the hepatitis A virus (HAV) and is usually transmitted through contaminated food or water or through close contact with someone who has the infection.
2. Hepatitis B: This type is caused by the hepatitis B virus (HBV) and can be spread through sexual contact, sharing of needles, or mother-to-child transmission during childbirth.
3. Hepatitis C: This type is caused by the hepatitis C virus (HCV) and is primarily spread through blood-to-blood contact, such as sharing of needles or receiving a tainted blood transfusion.
4. Alcoholic hepatitis: This type is caused by excessive alcohol consumption and can lead to inflammation and scarring in the liver.
5. Drug-induced hepatitis: This type is caused by certain medications, such as antidepressants, anti-seizure drugs, or chemotherapy agents.
6. Autoimmune hepatitis: This type is caused by an abnormal immune response and can lead to inflammation in the liver.
Symptoms of hepatitis may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, and yellowing of the skin (jaundice). In severe cases, it can lead to liver failure or even death.
Diagnosis of hepatitis is typically made through a combination of physical examination, laboratory tests such as blood tests and imaging studies like ultrasound or CT scans. Treatment options vary depending on the cause and severity of the condition, but may include medications to manage symptoms, antiviral therapy, or in severe cases, liver transplantation. Prevention measures for hepatitis include vaccination against certain types of the disease, practicing safe sex, avoiding sharing needles or other drug paraphernalia, and following proper hygiene practices.
In conclusion, hepatitis is a serious condition that affects millions of people worldwide. It is important to be aware of the different types of hepatitis and their causes in order to prevent and manage this condition effectively. By taking appropriate measures such as getting vaccinated and practicing safe sex, individuals can reduce their risk of contracting hepatitis. In severe cases, early diagnosis and treatment can help to minimize damage to the liver and improve outcomes for patients.
Hepatitis, chronic is a type of liver disease that is characterized by inflammation and damage to the liver, which can lead to scarring, cirrhosis, and potentially liver failure. It is caused by a variety of factors, including viral infections (such as hepatitis B and C), alcohol consumption, and autoimmune disorders.
Chronic hepatitis can be challenging to diagnose, as its symptoms are often nonspecific and may resemble those of other conditions. However, some common signs and symptoms include:
* Fatigue
* Loss of appetite
* Nausea and vomiting
* Abdominal pain
* Yellowing of the skin and eyes (jaundice)
* Dark urine
* Pale stools
If left untreated, chronic hepatitis can lead to serious complications, such as liver failure, liver cancer, and esophageal varices. Treatment options for chronic hepatitis depend on the underlying cause and may include medications, lifestyle changes, and in severe cases, liver transplantation.
Preventing Chronic Hepatitis:
While some forms of chronic hepatitis are incurable, there are steps you can take to prevent the development of this condition or slow its progression. These include:
* Avoiding alcohol or drinking in moderation
* Maintaining a healthy diet and lifestyle
* Getting vaccinated against hepatitis A and B
* Practicing safe sex to avoid sexually transmitted infections (STIs)
* Avoiding sharing needles or other drug-injecting equipment
* Seeking medical attention if you suspect you have been exposed to hepatitis
Managing Chronic Hepatitis:
If you have chronic hepatitis, managing the condition is crucial to prevent complications and improve quality of life. This may involve:
* Medications to treat the underlying cause of the hepatitis (e.g., antiviral drugs for hepatitis B or C)
* Lifestyle changes, such as avoiding alcohol and maintaining a healthy diet
* Regular monitoring of liver function and viral load
* In some cases, liver transplantation
Living with Chronic Hepatitis:
Living with chronic hepatitis can be challenging, but there are resources available to help you cope. These may include:
* Support groups for people with hepatitis and their families
* Counseling to address emotional and mental health concerns
* Educational resources to help you understand the condition and its management
* Legal assistance to navigate insurance and disability benefits
Conclusion:
Chronic hepatitis is a complex and multifactorial condition that can have serious consequences if left untreated. However, with early diagnosis, appropriate treatment, and lifestyle changes, it is possible to manage the condition and improve quality of life. By understanding the causes, symptoms, diagnosis, and management of chronic hepatitis, you can take an active role in your healthcare and make informed decisions about your care.
A viral infection that affects the liver and is transmitted to animals through contact with infected feces, urine, or saliva. The condition can be caused by several different viruses, including hepatitis A, B, C, D, and E. Symptoms of animal hepatitis may include loss of appetite, vomiting, diarrhea, lethargy, fever, and jaundice (yellowing of the skin and eyes). In severe cases, the infection can cause liver failure and death.
Prevention:
* Avoid contact with infected animals
* Practice good hygiene, such as washing hands frequently
* Keep pets up to date on vaccinations and preventatives
* Avoid drinking water or eating food that may be contaminated with feces or urine from infected animals
* Use protective clothing and equipment when handling animals that may be infected
Treatment:
* Supportive care, such as fluids and electrolytes to prevent dehydration and maintain blood pressure
* Antiviral medications in severe cases
* Hospitalization for severe cases or those that do not respond to treatment
Prognosis:
* Depends on the severity of the infection and the underlying health status of the animal. In general, the prognosis is good for animals that receive prompt and appropriate treatment.
Complications:
* Liver failure
* Sepsis (blood infection)
* Kidney failure
* Death
Prevalence:
* Widespread in animals, especially in those that are kept in close quarters or have poor living conditions.
Affected Organ:
* Liver
Symptoms of hepatitis E can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and yellowing of the skin and eyes (jaundice).
Hepatitis E is usually a self-limiting disease, meaning it will resolve on its own without treatment. However, in some cases, it can lead to fulminant hepatitis, which is a severe and potentially life-threatening form of liver disease.
There are several ways to diagnose hepatitis E, including blood tests to detect the presence of HEV antigens or antibodies, as well as imaging tests such as ultrasound or CT scans to evaluate liver function.
Treatment for hepatitis E is typically supportive, meaning it focuses on managing symptoms and maintaining hydration. In severe cases, hospitalization may be necessary to monitor and treat complications. Prevention of hepatitis E involves improving access to safe water and sanitation, as well as promoting good hygiene practices, such as washing hands regularly.
Vaccines are available for hepatitis E, but they are not widely available or recommended for most individuals. However, they may be recommended for certain high-risk groups, such as people living in areas with a high prevalence of HEV infection or those traveling to such areas.
The hepatitis D virus is transmitted through contact with infected blood or through sexual contact with an infected person. It can also be spread from mother to child during pregnancy or childbirth. Hepatitis D is a critical illness, and it can lead to liver failure, especially in people who are already infected with HBV.
There are two main types of hepatitis D: acute and chronic. Acute hepatitis D lasts for less than six months and typically resolves on its own without treatment. Chronic hepatitis D, on the other hand, can last for more than six months and can cause long-term liver damage.
Treatment for hepatitis D usually involves a combination of medications to manage symptoms and reduce inflammation in the liver. In severe cases, a liver transplant may be necessary. Prevention methods for hepatitis D include getting vaccinated against HBV, practicing safe sex, and avoiding sharing needles or other drug equipment.
Hepatitis D is a serious condition that can lead to complications such as liver failure, so it is important to seek medical attention if symptoms persist or worsen over time.
The condition can be caused by a variety of factors, including excessive alcohol consumption, viral hepatitis, non-alcoholic fatty liver disease, and certain medications. It can also be a complication of other diseases such as hemochromatosis and Wilson's disease.
The symptoms of liver cirrhosis can vary depending on the severity of the disease, but may include fatigue, loss of appetite, nausea, abdominal swelling, and pain in the upper right side of the abdomen. As the disease progresses, it can lead to complications such as esophageal varices, ascites, and liver failure, which can be life-threatening.
There is no cure for liver cirrhosis, but treatment options are available to manage the symptoms and slow the progression of the disease. These may include medications to control swelling and pain, dietary changes, and in severe cases, liver transplantation. In some cases, a liver transplant may be necessary if the disease has caused significant damage and there is no other option to save the patient's life.
In conclusion, liver cirrhosis is a serious and potentially life-threatening condition that can cause significant damage to the liver and lead to complications such as liver failure. It is important for individuals to be aware of the risk factors and symptoms of the disease in order to seek medical attention if they suspect they may have liver cirrhosis. With proper treatment and management, it is possible to slow the progression of the disease and improve the patient's quality of life.
In animals, hepatitis can be caused by a variety of agents, including:
1. Viral hepatitis: Caused by viruses such as feline infectious peritonitis (FIP) in cats and canine infectious hepatitis (CIH) in dogs.
2. Bacterial hepatitis: Caused by bacteria such as Leptospira spp., which can be transmitted through contact with contaminated water or soil.
3. Parasitic hepatitis: Caused by parasites such as liver flukes (Fasciola spp.) and tapeworms (Taenia spp.).
4. Toxic hepatitis: Caused by exposure to certain drugs, chemicals, or environmental toxins.
5. Genetic hepatitis: Caused by inherited genetic disorders such as hemophilia in dogs and cats.
The clinical signs of animal hepatitis can vary depending on the cause and severity of the disease, but may include lethargy, loss of appetite, vomiting, diarrhea, abdominal pain, and jaundice (yellowing of the skin and eyes). Diagnosis is based on a combination of physical examination, laboratory tests (such as blood tests and liver biopsy), and imaging studies.
Treatment of animal hepatitis depends on the underlying cause and may include supportive care, antibiotics, anti-inflammatory medications, and in some cases, surgery or liver transplantation. In severe cases, animal hepatitis can be fatal if left untreated, so early diagnosis and aggressive treatment are essential for a successful outcome.
Jaundice is typically diagnosed through physical examination and laboratory tests such as blood tests to measure bilirubin levels. Treatment depends on the underlying cause, but may include medications to reduce bilirubin production or increase its excretion, or surgery to remove blockages in the bile ducts.
Here are some of the synonyms for Jaundice:
1. Yellow fever
2. Yellow jaundice
3. Hepatitis
4. Gallstones
5. Cholestasis
6. Obstruction of the bile ducts
7. Biliary tract disease
8. Hemochromatosis
9. Sickle cell anemia
10. Crigler-Najjar syndrome
Here are some of the antonyms for Jaundice:
1. Pinkness
2. Normal skin color
3. Healthy liver function
4. Bilirubin levels within normal range
5. No signs of liver disease or obstruction of bile ducts.
The exact cause of autoimmune hepatitis is not fully understood, but it is believed to involve a combination of genetic and environmental factors. The condition can occur in people of all ages, although it is most common in women between the ages of 20 and 40.
Symptoms of autoimmune hepatitis may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, and yellowing of the skin and eyes (jaundice). If left untreated, the condition can lead to liver failure and even death.
Treatment for autoimmune hepatitis typically involves medications to suppress the immune system and reduce inflammation in the liver. In severe cases, a liver transplant may be necessary. Early diagnosis and treatment can improve the chances of a successful outcome.
There are many different types of liver diseases, including:
1. Alcoholic liver disease (ALD): A condition caused by excessive alcohol consumption that can lead to inflammation, scarring, and cirrhosis.
2. Viral hepatitis: Hepatitis A, B, and C are viral infections that can cause inflammation and damage to the liver.
3. Non-alcoholic fatty liver disease (NAFLD): A condition where there is an accumulation of fat in the liver, which can lead to inflammation and scarring.
4. Cirrhosis: A condition where the liver becomes scarred and cannot function properly.
5. Hemochromatosis: A genetic disorder that causes the body to absorb too much iron, which can damage the liver and other organs.
6. Wilson's disease: A rare genetic disorder that causes copper to accumulate in the liver and brain, leading to damage and scarring.
7. Liver cancer (hepatocellular carcinoma): Cancer that develops in the liver, often as a result of cirrhosis or viral hepatitis.
Symptoms of liver disease can include fatigue, loss of appetite, nausea, abdominal pain, dark urine, pale stools, and swelling in the legs. Treatment options for liver disease depend on the underlying cause and may include lifestyle changes, medication, or surgery. In severe cases, a liver transplant may be necessary.
Prevention of liver disease includes maintaining a healthy diet and lifestyle, avoiding excessive alcohol consumption, getting vaccinated against hepatitis A and B, and managing underlying medical conditions such as obesity and diabetes. Early detection and treatment of liver disease can help to prevent long-term damage and improve outcomes for patients.
There are several risk factors for developing HCC, including:
* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity
HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:
* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss
If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:
* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope
Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:
* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer
Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.
Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.
There are several types of liver neoplasms, including:
1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.
The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.
Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.
Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.
Examples of acute diseases include:
1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.
Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.
Hepatitis, Alcoholic: A type of hepatitis (inflammation of the liver) caused by excessive alcohol consumption over a long period of time. It is characterized by fatty degeneration of liver cells, inflammation, and fibrosis (scarring). The condition can progress to cirrhosis if left untreated.
The term "alcoholic hepatitis" does not refer only to alcohol-related liver disease but also includes other conditions such as fatty liver disease caused by excessive alcohol consumption.
Causes: The exact cause of alcoholic hepatitis is not fully understood, but it is believed that long-term heavy drinking can damage liver cells and lead to inflammation.
Symptoms: Symptoms of alcoholic hepatitis can range from mild to severe and include fatigue, loss of appetite, nausea, vomiting, abdominal pain, fever, and jaundice (yellowing of the skin and eyes).
Diagnosis: Diagnosis is based on a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound or CT scans.
Treatment: Treatment for alcoholic hepatitis typically involves stopping drinking altogether, nutritional support, and medication to manage symptoms. In severe cases, hospitalization may be necessary to monitor and treat complications.
Prevention: Preventing alcoholic hepatitis involves avoiding excessive alcohol consumption and seeking medical attention if symptoms persist or worsen over time.
Prognosis: The prognosis for alcoholic hepatitis depends on the severity of the condition and how well the individual responds to treatment. In severe cases, liver transplantation may be necessary.
This condition is most commonly seen in people with advanced liver disease, such as cirrhosis or liver cancer. It can also be caused by other conditions that affect the liver, such as hepatitis or portal hypertension.
Symptoms of hepatic encephalopathy can include confusion, disorientation, slurred speech, memory loss, and difficulty with coordination and balance. In severe cases, it can lead to coma or even death.
Diagnosis of hepatic encephalopathy is typically made through a combination of physical examination, medical history, and diagnostic tests such as blood tests and imaging studies. Treatment options include medications to reduce the production of ammonia in the gut, antibiotics to treat any underlying infections, and transjugular intrahepatic portosystemic shunt (TIPS) to improve liver function. In severe cases, a liver transplant may be necessary.
Overall, hepatic encephalopathy is a serious condition that can have significant impact on quality of life and survival in people with advanced liver disease. Early detection and prompt treatment are essential to prevent complications and improve outcomes.
Chronic hepatitis D can cause inflammation and damage to the liver, leading to scarring and cirrhosis. It can also increase the risk of developing liver cancer. Treatment options for chronic hepatitis D are limited and may include antiviral medications, pegylated interferon, and liver transplantation in severe cases.
Prevention of chronic hepatitis D primarily involves avoiding exposure to HBV, which is the primary risk factor for HDV infection. This can be achieved through vaccination against HBV, safe sex practices, and avoiding sharing of needles or other injection equipment.
Causes:
1. Viral hepatitis (hepatitis A, B, or C)
2. Overdose of medications or supplements
3. Toxic substances (e.g., alcohol, drugs, or chemicals)
4. Sepsis or other infections that spread to the liver
5. Certain autoimmune disorders (e.g., hemochromatosis, Wilson's disease)
6. Cancer that has metastasized to the liver
7. Blood vessel blockage or clotting in the liver
8. Lack of blood flow to the liver
Symptoms:
1. Jaundice (yellowing of skin and eyes)
2. Nausea and vomiting
3. Abdominal swelling and discomfort
4. Fatigue, weakness, and loss of appetite
5. Confusion or altered mental state
6. Seizures or coma
7. Pale or clay-colored stools
8. Dark urine
Diagnosis:
1. Physical examination and medical history
2. Laboratory tests (e.g., liver function tests, blood tests, imaging studies)
3. Biopsy of the liver tissue (to rule out other liver diseases)
Treatment:
1. Supportive care (fluids, nutrition, and medication to manage symptoms)
2. Addressing underlying causes (e.g., stopping alcohol or drug use, treating infections)
3. Transjugular intrahepatic portosystemic shunt (TIPS), a procedure that creates a new pathway for blood to flow through the liver
4. Liver transplantation (in severe cases where other treatments have failed)
Prognosis:
The prognosis for acute liver failure depends on the underlying cause of the condition and the severity of the liver damage. In general, the earlier the diagnosis and treatment, the better the outcome. However, acute liver failure can be a life-threatening condition, and the mortality rate is high, especially in cases where there is severe liver damage or no available donor liver for transplantation.
The definition of DILI has been revised several times over the years, but the most recent definition was published in 2013 by the International Consortium for DILI Research (ICDCR). According to this definition, DILI is defined as:
"A clinically significant alteration in liver function that is caused by a medication or other exogenous substance, and is not related to underlying liver disease. The alteration may be biochemical, morphological, or both, and may be acute or chronic."
The ICDCR definition includes several key features of DILI, including:
1. Clinically significant alteration in liver function: This means that the liver damage must be severe enough to cause symptoms or signs of liver dysfunction, such as jaundice, nausea, vomiting, or abdominal pain.
2. Caused by a medication or other exogenous substance: DILI is triggered by exposure to certain drugs or substances that are not related to underlying liver disease.
3. Not related to underlying liver disease: This means that the liver damage must not be caused by an underlying condition such as hepatitis B or C, alcoholic liver disease, or other genetic or metabolic disorders.
4. May be acute or chronic: DILI can occur as a sudden and severe injury (acute DILI) or as a slower and more insidious process (chronic DILI).
The ICDCR definition provides a standardized way of defining and diagnosing DILI, which is important for clinicians and researchers to better understand the cause of liver damage in patients who are taking medications. It also helps to identify the drugs or substances that are most likely to cause liver injury and to develop strategies for preventing or treating DILI.
HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.
There are several ways that HIV can be transmitted, including:
1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)
The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:
1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss
If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:
1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)
HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.
Prevention methods for HIV infection include:
1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.
It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.
The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.
In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.
What is a Chronic Disease?
A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:
1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke
Impact of Chronic Diseases
The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.
Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.
Addressing Chronic Diseases
Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:
1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.
Conclusion
Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.
The term "alcoholic" in this context refers to the fact that the damage is caused by excessive alcohol consumption, rather than any other underlying medical condition or disease process. The suffix "-osis" means "condition" or "disease," and "alcoholic" modifies the noun "liver cirrhosis" to indicate the cause of the condition.
The term "LC-ALD" is used in medical literature and research to specifically refer to this type of cirrhosis caused by alcohol consumption, as opposed to other types of cirrhosis that may be caused by viral hepatitis or other factors.
There are several causes of liver failure, including:
1. Alcohol-related liver disease: Prolonged and excessive alcohol consumption can damage liver cells, leading to inflammation, scarring, and eventually liver failure.
2. Viral hepatitis: Hepatitis A, B, and C are viral infections that can cause inflammation and damage to the liver, leading to liver failure.
3. Non-alcoholic fatty liver disease (NAFLD): A condition where there is an accumulation of fat in the liver, leading to inflammation and scarring.
4. Drug-induced liver injury: Certain medications can cause liver damage and failure, especially when taken in high doses or for extended periods.
5. Genetic disorders: Certain inherited conditions, such as hemochromatosis and Wilson's disease, can cause liver damage and failure.
6. Acute liver failure: This is a sudden and severe loss of liver function, often caused by medication overdose or other toxins.
7. Chronic liver failure: A gradual decline in liver function over time, often caused by cirrhosis or NAFLD.
Symptoms of liver failure can include:
1. Jaundice (yellowing of the skin and eyes)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain
6. Confusion and altered mental state
7. Easy bruising and bleeding
Diagnosis of liver failure is typically made through a combination of physical examination, medical history, and laboratory tests, such as blood tests to check for liver enzymes and bilirubin levels. Imaging tests, such as ultrasound and CT scans, may also be used to evaluate the liver.
Treatment of liver failure depends on the underlying cause and severity of the condition. In some cases, a liver transplant may be necessary. Other treatments may include medications to manage symptoms, such as nausea and pain, and supportive care to maintain nutrition and hydration. In severe cases, hospitalization may be required to monitor and treat complications.
Prevention of liver failure is important, and this can be achieved by:
1. Avoiding alcohol or drinking in moderation
2. Maintaining a healthy weight and diet
3. Managing underlying medical conditions, such as diabetes and high blood pressure
4. Avoiding exposure to toxins, such as certain medications and environmental chemicals
5. Getting vaccinated against hepatitis A and B
6. Practicing safe sex to prevent the spread of hepatitis B and C.
There are two main types of fatty liver disease:
1. Alcoholic fatty liver disease (AFLD): This type of fatty liver disease is caused by excessive alcohol consumption and is the most common cause of fatty liver disease in the United States.
2. Non-alcoholic fatty liver disease (NAFLD): This type of fatty liver disease is not caused by alcohol consumption and is the most common cause of fatty liver disease worldwide. It is often associated with obesity, diabetes, and high cholesterol.
There are several risk factors for developing fatty liver disease, including:
* Obesity
* Physical inactivity
* High calorie intake
* Alcohol consumption
* Diabetes
* High cholesterol
* High triglycerides
* History of liver disease
Symptoms of fatty liver disease can include:
* Fatigue
* Abdominal discomfort
* Loss of appetite
* Nausea and vomiting
* Abnormal liver function tests
Diagnosis of fatty liver disease is typically made through a combination of physical examination, medical history, and diagnostic tests such as:
* Liver biopsy
* Imaging studies (ultrasound, CT or MRI scans)
* Blood tests (lipid profile, glucose, insulin, and liver function tests)
Treatment of fatty liver disease depends on the underlying cause and severity of the condition. Lifestyle modifications such as weight loss, exercise, and a healthy diet can help improve the condition. In severe cases, medications such as antioxidants, fibric acids, and anti-inflammatory drugs may be prescribed. In some cases, surgery or other procedures may be necessary.
Prevention of fatty liver disease includes:
* Maintaining a healthy weight
* Eating a balanced diet low in sugar and saturated fats
* Engaging in regular physical activity
* Limiting alcohol consumption
* Managing underlying medical conditions such as diabetes and high cholesterol.
Symptoms of influenza include:
* Fever (usually high)
* Cough
* Sore throat
* Runny or stuffy nose
* Headache
* Muscle or body aches
* Fatigue (tiredness)
* Diarrhea and nausea (more common in children than adults)
Influenza can lead to serious complications, such as pneumonia, bronchitis, and sinus and ear infections. These complications are more likely to occur in people who have a weakened immune system, such as the elderly, young children, and people with certain chronic health conditions (like heart disease, diabetes, and lung disease).
Influenza is diagnosed based on a physical examination and medical history. A healthcare provider may also use a rapid influenza test (RIT) or a polymerase chain reaction (PCR) test to confirm the diagnosis.
Treatment for influenza typically involves rest, hydration, and over-the-counter medications such as acetaminophen (Tylenol) or ibuprofen (Advil, Motrin) to relieve fever and body aches. Antiviral medications, such as oseltamivir (Tamiflu) or zanamivir (Relenza), may also be prescribed to help shorten the duration and severity of the illness. However, these medications are most effective when started within 48 hours of the onset of symptoms.
Prevention is key in avoiding influenza. Vaccination is the most effective way to prevent influenza, as well as practicing good hygiene such as washing your hands frequently, avoiding close contact with people who are sick, and staying home when you are sick.
There are several types of alcoholic liver diseases, including:
1. Alcoholic fatty liver disease (AFLD): This condition occurs when there is an accumulation of fat in the liver cells due to excessive alcohol consumption. It is the earliest stage of alcohol-related liver disease and can be reversed with abstinence from alcohol.
2. Alcoholic hepatitis (AH): This condition is characterized by inflammation of the liver, which can lead to scarring and liver failure. It is more common in individuals who consume heavy amounts of alcohol over a long period.
3. Cirrhosis: This is a chronic condition where the liver becomes scarred and cannot function properly. It is often irreversible and can lead to liver failure, heart disease, and other complications.
4. Liver failure: This is the most severe stage of alcoholic liver disease, where the liver fails to function entirely. It can be fatal if not treated promptly with a liver transplant or other medical interventions.
The symptoms of alcoholic liver disease can vary depending on the severity of the condition and may include fatigue, nausea, loss of appetite, abdominal pain, and yellowing of the skin and eyes (jaundice). Treatment for alcoholic liver disease typically involves abstinence from alcohol, medication to manage symptoms, and in severe cases, a liver transplant.
Prevention is key in avoiding alcoholic liver disease. Limiting alcohol intake, maintaining a healthy diet, and avoiding harmful substances can help reduce the risk of developing this condition. Early detection and intervention are also crucial in managing the condition before it progresses to more severe stages.
If you or someone you know is struggling with alcohol addiction, there are many resources available to help. Seeking professional assistance from a healthcare provider, therapist, or support group can provide the necessary tools and guidance to overcome alcoholism and prevent alcoholic liver disease.
Hepatitis B vaccine
Hepatitis A vaccine
Hepatitis C vaccine
Hepatitis B virus
Yellow fever vaccine
E2 (HCV)
Ronald C. Kennedy
CD74
World Hepatitis Day
Dermot P. Kelleher
Chi-Ming Chu
Leeuwenhoek Lecture
RG7795
Erzsébet Simonyi
HPV vaccine
Hepatitis B
PKIDs
DA2PPC vaccine
Mosquito-borne disease
Yves Lévy
HLA-A1
Viral hepatitis
Global HIV Vaccine Enterprise
Genetically modified virus
Hayward Medical Communications
Association of Public Health Laboratories
Hepatitis A
Hepadnaviridae
California Department of Public Health
HPV Prevention and Control Board
Interferon
Diseases of poverty
Robert Huebner
Barrie Marmion
Ștefan S. Nicolau
Antimicrobial
Gene delivery
Viral envelope
Telomerase
Hypogammaglobulinemia
Vaccine hesitancy
Cancer
Zoonosis
Spleen
Surrogate endpoint
CLEC5A
Refugee health
Pestivirus
Chloe Orkin
Genome editing
Medical microbiology
Parvovirus B19
Allergy
National Institute of Virology
Tumor antigens recognized by T lymphocytes
Tilapia tilapinevirus
Biopharmaceutical
Browsing by Subject "Viral Hepatitis Vaccines"
In the fight against viral hepatitis A, vaccines save lives | NIH Intramural Research Program
Recommendation of the Immunization Practices Advisory
Committee (ACIP)
Inactivated Hepatitis B Virus Vaccine
Seroprevalence for Hepatitis E and Other Viral Hepatitides among Diverse Populations, Malawi - Volume 21, Number 7-July 2015 -...
Hepatology Fellowship Program - NIDDK
Featured news | WHO | Regional Office for Africa
Licensure of Inactivated Hepatitis A Vaccine & Recom. for Int'l ...
Structure of hepatitis C proteins reveals viral vulnerabilities | National Institutes of Health (NIH)
Browsing Meeting reports by Subject
Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis -...
Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization...
Advanced Search Results - Public Health Image Library(PHIL)
DailyMed - RECOMBIVAX HB (hepatitis b vaccine- recombinant injection, suspension
PA-12-038: Research to Advance Vaccine Safety (R21)
Mascola, John 2022 - Office of NIH History and Stetten Museum
Hepatitis C Quiz: Symptoms, Treatment, Vaccine & Cure
WHO EMRO | First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya | Volume 19,...
Hepatitis B | HBV | MedlinePlus
Biomarkers Search
Intradermal hepatitis B vaccination in a large hospital employee population
Types of Viral Hepatitis | National Institute on Drug Abuse (NIDA)
NIH Clinical Center Search the Studies: Study Number, Study Title
Viral Hepatitis Prevention Program Practices | NPIN
Hepatitis | MedlinePlus
MeSH Browser
Activities of the Cadham Provincial Laboratory - Cadham Provincial Laboratory | Health | Province of Manitoba
ABCs of Viral Hepatitis | Blogs | CDC
Chronic Inflammation of the Oral Cavity - An Agent for Oral Mucosal Disease | National Institute of Dental and Craniofacial...
P HEPBD
Infection35
- Clinical characterization of HEV infection is similar to that of other viral hepatitis infections, ranging from asymptomatic infection to fulminant hepatitis ( 2 ). (cdc.gov)
- Unlike HAV and HEV, hepatitis B and C viruses (HBV and HCV) are transmitted through contact with infectious body fluids and can cause acute or chronic infection. (cdc.gov)
- The Hepatitis C virus (HCV) is a blood-borne virus that causes liver infection. (medicinenet.com)
- Hepatitis C infection is extremely contagious. (medicinenet.com)
- This can occur secondary to infection with many infections, including Hepatitis C virus. (medicinenet.com)
- Up to one-quarter of people infected with Hepatitis C will rid the virus from their bodies without treatment and not experience chronic infection. (medicinenet.com)
- There are many new and promising medical treatments for Hepatitis C infection. (medicinenet.com)
- The Centers for Disease Control (CDC) estimates between 2.4 million and 3.9 million people are living with chronic Hepatitis C infection. (medicinenet.com)
- Hepatitis C infection kills more people annually than HIV/AIDS. (medicinenet.com)
- Hepatitis C infection can be cured in certain cases. (medicinenet.com)
- In February 1995, Havrix(R) * , an inactivated hepatitis A vaccine distributed by SmithKline Beecham Pharmaceuticals (Philadelphia, Pennsylvania) was licensed by the Food and Drug Administration for use in persons aged greater than or equal to 2 years to prevent hepatitis A virus (HAV) infection. (cdc.gov)
- Prevaccination serologic testing may be indicated for adult travelers who probably have had prior HAV infection if the cost of testing is less than the cost of vaccination and if testing will not interfere with completion of the vaccine series. (cdc.gov)
- Despite years of effort, researchers have not yet developed an effective vaccine that prevents infection. (nih.gov)
- RECOMBIVAX HB is a vaccine indicated for prevention of infection caused by all known subtypes of hepatitis B virus. (nih.gov)
- Some people with acute hepatitis B have symptoms 2 to 5 months after infection. (medlineplus.gov)
- But if you have a chronic infection and blood tests show that hepatitis B could be damaging your liver, you may need to take antiviral medicines. (medlineplus.gov)
- Your provider may give you a dose of the hepatitis B vaccine to prevent infection. (medlineplus.gov)
- Active uncontrolled bacterial, viral, or fungal infection. (nih.gov)
- Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. (nih.gov)
- 8. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. (nih.gov)
- This increase is believed to be related to infection with hepatitis B or hepatitis C. (cdc.gov)
- Hepatitis A is a short-term disease caused by infection with the hepatitis A virus. (cdc.gov)
- Hepatitis B is a liver disease that results after infection with the hepatitis B virus. (cdc.gov)
- For instance, there are different types of drugs available to treat a wide range of liver related disorders such as antiviral drugs are utilized for treatment of hepatitis viral infection. (alliedmarketresearch.com)
- In addition, other drugs used to cure liver related medical conditions include immunoglobulins, which are obtained from plasma of patients who have recovered from hepatitis B viral infection. (alliedmarketresearch.com)
- People who use drugs have the right to be protected from hepatitis B infection, to know their hepatitis B status, and to have equitable and affordable access to prevention, treatment and care. (hepatitisaustralia.com)
- Chronic infection of hepatitis B and C affects the liver overtime and causes cirrhosis and eventually liver cancer. (modernghana.com)
- Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. (cdc.gov)
- Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States . (cdc.gov)
- and persons with a history of hepatitis C virus infection. (cdc.gov)
- Persons with chronic hepatitis B virus (HBV) infection are at increased risk for liver cancer and cirrhosis and are 70%-85% more likely to die prematurely than the general population ( 1 - 4 ). (cdc.gov)
- To provide a framework for reaching the World Health Organization's viral hepatitis elimination goals, the Viral Hepatitis National Strategic Plan for the United States calls for an increase in the proportion of persons with HBV infection who are aware of their infection from 32% (2013-2016) to 90% by 2030 ( 12 , 13 ). (cdc.gov)
- The three main serologic markers used to determine HBV infection status are hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) ( Table 1 ). (cdc.gov)
- The presence of HBsAg indicates HBV infection, either acute or chronic, except when it might be transiently positive shortly after a dose of HepB vaccine ( 16 ). (cdc.gov)
- Hepatitis B is a viral infection that attacks the liver and can cause acute and chronic disease. (case.edu)
Division of Viral Hepatitis2
- Sign up for email updates from CDC's Division of Viral Hepatitis . (cdc.gov)
- As you begin deliberations on the Fiscal Year 2015 Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, we would like to respectfully request that you allocate $47.8 million for the Division of Viral Hepatitis (DVH) at the Centers for Disease Control and Prevention (CDC), an increase of $16.4 million over the FY2014 level. (hepb.org)
Prevent hepatitis4
- The best way to prevent hepatitis B is to get the hepatitis B vaccine. (medlineplus.gov)
- There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. (nih.gov)
- There is currently no vaccine to prevent hepatitis C. Fortunately, new treatments offer a cure for most people. (cdc.gov)
- Effective vaccines to prevent hepatitis B are available. (cdc.gov)
Vaccination19
- There is a vaccination against hepatitis C. (medicinenet.com)
- Discuss the need for Hepatitis A or B vaccination with a doctor. (medicinenet.com)
- The results suggest that intradermal vaccination with hepatitis B vaccine may be appropriate under certain conditions and for certain population subgroups. (nih.gov)
- Decisions about when to administer an intramuscular vaccine, including RECOMBIVAX HB, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination. (nih.gov)
- ABSTRACT The hepatitis B virus (HBV) vaccination schedule in Libya follows international recommendations (1st dose at birth, 2nd after 1 month and 3rd after 6 months). (who.int)
- The response to HBV vaccine in 1-3-year-olds was 93.2%, but this declined with age and at 7-9 years after initial vaccination only 53.1% of children had protective titres (≥ 10 mIU/mL). (who.int)
- RÉSUMÉ Le calendrier de vaccination contre le virus de l'hépatite B en Libye suit les recommandations internationales (première dose à la naissance, deuxième dose un mois après et troisième dose six mois après). (who.int)
- Viral (hepatitis B virus): Both GLPLS and lichen planus have been reported to be rare events following hepatitis B virus vaccination. (medscape.com)
- 7. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. (nih.gov)
- The assessment takes only five minutes and will provide personalized testing and vaccination recommendations for hepatitis A, hepatitis B, and hepatitis C. (cdc.gov)
- Vaccines segment is expected to witness a decline owing to the fact that vaccination programs were put on hold to concentrate on medical care for COVID-19. (alliedmarketresearch.com)
- The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. (mdpi.com)
- The Declaration endorsed by 6th APCAT Summit further underlines: "We commit to doing everything to harness the power of our city governments to ensure that tobacco control, prevention of non-communicable diseases, TB control, elimination of viral hepatitis, routine immunization and scaling up Covid vaccination are effectively implemented and measured, along with other health and development initiatives, and the recovery from Covid is healthy, equitable and sustainable. (modernghana.com)
- Along with Singapore, other countries like Bangladesh, Bhutan, Thailand, Malaysia, and Nepal have also successfully met the WHO target for 2020 of achieving 90% prevention of hepatitis B through vaccination (by providing birth dose of hepatitis B vaccine to newborn children). (modernghana.com)
- Vaccination is the foundation of prevention of hepatitis B virus (HBV)" said Dr Po-Lin Chan. (modernghana.com)
- Their new study, "Pre-Vaccination Inflammation and B-cell Signaling Predict Age-related Hyporesponse to Hepatitis B Vaccination," was published in the current issue of Nature Communications . (case.edu)
- Vaccination is a proven approach to preventing diseases such as hepatitis B, but low age-related response caused by changes to the immune system can limit the effectiveness in the elderly. (case.edu)
- Additionally, hepatitis A vaccination is recommended for person considered at high risk for developing hepatitis A related to travel, employment, pre-existing health issues, lifestyle and in the event of an outbreak situation. (nvic.org)
- NVIC encourages you to become fully informed about Hepatitis A and the Hepatitis A vaccine by reading all sections in the Table of Contents below, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. (nvic.org)
20234
- The National Hepatitis B Strategy 2023-2030 and the National Hepatitis C Strategy 2023-2030 (the Strategies) have been released for public consultation by the Department of Health and Aged Care. (hepatitisaustralia.com)
- The International HIV Coinfection + Viral Hepatitis Elimination Conference will be taking place in Brisbane, Australia ahead of IAS 2023. (hepatitisaustralia.com)
- On May 11, 2023, Action Hepatitis Canada (AHC) released its Progress Toward Viral Hepatitis Elimination in Canada 2023 Report . (catie.ca)
- We updated them for the 2023 report to include hepatitis B metrics and to more closely align with the WHO targets, as these were included in the pan-Canadian framework for action , as well as the Canadian government's five-year action plan , which was endorsed by all provinces and territories. (catie.ca)
Acute9
- The hepatitis A virus causes contagious, acute inflammation of the liver. (nih.gov)
- 1973). Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness . (nih.gov)
- In northern Uganda, surveillance of health care facilities during 2010-2012 showed that 42% of 347 persons with reported acute jaundice syndrome cases had hepatitis E, 14% had hepatitis B, and 5% had hepatitis C ( 5 ). (cdc.gov)
- An estimated 30,500 acute hepatitis C cases occurred in 2014. (medicinenet.com)
- In rare cases, acute hepatitis B can cause liver failure. (medlineplus.gov)
- If you have acute hepatitis B, you probably don't need treatment. (medlineplus.gov)
- Some types of hepatitis cause only acute infections. (nih.gov)
- Treatment for hepatitis depends on which type you have and whether it is acute or chronic. (nih.gov)
- Acute viral hepatitis often goes away on its own. (nih.gov)
Immunization9
- The Advisory Committee on Immunization Practices (ACIP) offers the following interim recommendations for the use of inactivated hepatitis A vaccine among international travelers. (cdc.gov)
- 17. Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. (nih.gov)
- Moreover, liver diseases also include use of vaccines to provide immunization against viral hepatitis. (alliedmarketresearch.com)
- For instance, vaccines suffered a negative impact as immunization programs were halted. (alliedmarketresearch.com)
- These changes may play a role in immunization failure, but other factors including viral load may be more important. (deepdyve.com)
- HBV, immunization, HBsAg mutants, vaccine escape, viral load, infected infants Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) represents an important mechanism for the generation and maintenance of persistent infections within populations. (deepdyve.com)
- The World Health Organization's recommendation for national HBV immunization programs worldwide is aimed at eliminating perinatal transmission through active HBV immunization within 24 hours of birth with the addition of hepatitis B immune globulin (HBIG) where there is a high risk of transmission [2]. (deepdyve.com)
- The U.S. Food and Drug Administration and U.S. Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control (CDC) has approved three different hepatitis A containing shots. (nvic.org)
- The CDC's Advisory Committee on Immunization Practices currently recommends that all children receive the first dose of hepatitis A vaccine between 12 and 23 months of age and the second dose is recommended 6 months or longer following the first dose of the vaccine. (nvic.org)
People with hepatitis4
- Often, people with hepatitis B don't have symptoms. (medlineplus.gov)
- Some people with hepatitis do not have symptoms and do not know they are infected. (nih.gov)
- Once diagnosed, most people with hepatitis C can be cured in just 8 to 12 weeks, which reduces their risk for liver cancer. (cdc.gov)
- Asia and the Pacific has more than half of world's total number of people with hepatitis B and C virus. (modernghana.com)
Efficacy4
- IRP researchers Robert Purcell, M.D. , Albert Kapikian, M.D. , Stephen Feinstone, M.D., and colleagues played a crucial role in developing the first licensed hepatitis A vaccine, from initial identification and characterization of the virus to the clinical trials that demonstrated protective efficacy a glimpse of history . (nih.gov)
- Based on a controlled clinical trial, the efficacy of two doses of vaccine (360 enzyme-linked immunosorbent assay units) administered 1 month apart in preventing hepatitis A in children was estimated to be 94% (95% confidence interval=79%-99%) (3). (cdc.gov)
- Despite these drawbacks, some nucleoside analogues have been found efficacious against hepatitis B virus and it is likely that as knowledge of their mechanism of action accumulates, their efficacy can be improved both by rational drug design and by use in combination with other drugs, including interferon. (edu.au)
- Continued monitoring of vaccine efficacy is essential. (deepdyve.com)
Antibody5
- Immunogenicity studies have indicated that virtually 100% of children, adolescents, and adults develop protective levels of antibody to hepatitis A virus (anti-HAV) after completing the vaccine series (1,2). (cdc.gov)
- When immune globulin (IG) is given concurrently with the first dose of vaccine, the proportion of persons who develop protective levels of anti-HAV is not affected, but antibody concentrations are lower. (cdc.gov)
- Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen. (nih.gov)
- No significant differences between males and females in antibody persistence or response to vaccine were observed. (who.int)
- 1999. Viral persistence, antibody to e1 and e2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. (nationalacademies.org)
Recombinant1
- a combination vaccine containing both inactivated hepatitis A virus vaccine (HAVRIX) and recombinant hepatitis B vaccine (ENGERIX-B), manufactured by GlaxoSmithKline. (nvic.org)
Surface antigen3
- Serum levels of hepatitis B surface antigen were determined in 277 randomly selected children aged 1-12 years. (who.int)
- Sequencing and epitope phenotyping were used to investigate alterations in hepatitis B surface antigen (HBsAg) sequence and antigenicity in infants and in mothers known to have transmitted and not to have transmitted virus to their infants. (deepdyve.com)
- Optimally implemented, these actions have had a dramatic impact on reducing MTCT, with an 87% reduction observed in the seroprevalence of hepatitis B surface antigen (HBsAg) in children in countries of previous high endemicity [3]. (deepdyve.com)
Centers2
- 1 Division of Viral and Rickettsial Diseases, Centers for Disease Control, Atlanta, GA 30333. (nih.gov)
- To assess more adequately the immunogenicity of hepatitis B vaccine using the intradermal route, the Centers for Disease Control conducted a clinical trial among 425 well health-care workers in a hospital setting. (nih.gov)
Elimination6
- 15. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. (nih.gov)
- Elimination of viral hepatitis should be part of any sound public health agenda. (modernghana.com)
- The Mayors and other subnational leaders and delegates of APCAT Summit adopted an APCAT Declaration 2021 which includes the promise for "addressing the challenge of viral hepatitis as a major public health threat in the Asia Pacific region through elimination of mother to child transmission by raising public awareness and strengthening health systems through public and private partnerships. (modernghana.com)
- Dr Po-Lin Chan from Manila-based World Health Organization (WHO)'s Western Pacific regional office said that "Elimination of viral hepatitis as a public health threat by 2030 is a combination of existing interventions at scale. (modernghana.com)
- These barriers to achieving viral hepatitis elimination will remain if we do not take a reconciliatory approach to healthcare for Indigenous people, and address inequities in healthcare access for people living in remote and rural areas, as well as for those structurally excluded from mainstream healthcare and society more broadly. (catie.ca)
- Each jurisdiction must create and implement its own strategy toward viral hepatitis elimination. (catie.ca)
Diseases7
- Today's date is Monday, March 21, 2022, and I am speaking with Dr. John Mascola for the Vaccine Research Center with the National Institute of Allergies and Infectious Diseases, which is part of the National Institutes of Health, or NIH. (nih.gov)
- Dr. Mascola is the director of the Dale and Betty Bumpers Vaccine Research Center, or VRC, at the National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health. (nih.gov)
- So, I'm quite sure that seeing the first early AIDS patients who did not do well and seeing a viral disease that could destroy the immune system without a clear understanding of what was happening or how to benefit those patients really inspired me toward a career in infectious diseases, and, more specifically, towards a research career in viral immunology. (nih.gov)
- Surveillance and diagnostic testing in support of Public Health Programs, e.g. prenatal screening for HIV, Syphilis, Hepatitis Band immune status testing for Rubella;Serodiagnostic testing for viral, bacterial and parasitic diseases, e.g. (gov.mb.ca)
- Liver disease treatments are defined as any medical care provided to the patient suffering from liver diseases in form of vaccines and drugs. (alliedmarketresearch.com)
- Hepatitis B (HB) and C (HC) are two severe viral infectious diseases with a deleterious impact on global health. (biomedcentral.com)
- No mRNA vaccine has been approved for use in any disease, although some are in clinical trials for other diseases. (melvinkonner.com)
Immune globulin2
- In some cases, your provider may also give you a medicine called hepatitis B immune globulin (HBIG). (medlineplus.gov)
- Results Vaccine/hepatitis B immune globulin uptake was complete in the majority of HBV-infected infants. (deepdyve.com)
Virus43
- Prior to the discovery of a vaccine, an estimated 100 people died from it every year in the U.S. Hepatitis A With no treatments, creating a vaccine against the hepatitis A virus could reduce incidence of the disease and save lives Hepatitis A FAQs for Health Professionals . (nih.gov)
- 1981). Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage . (nih.gov)
- Worldwide, recommendations for using hepatitis B virus (HBV) vaccine will vary in accordance with local patterns of HBV transmission. (cdc.gov)
- Data on prevalence of hepatitis E virus (HEV) in Malawi is limited. (cdc.gov)
- We tested blood samples from HIV-uninfected and -infected populations of women and men enrolled in research studies in Malawi during 1989-2008 to determine the seroprevalence of HEV, hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). (cdc.gov)
- Hepatitis E virus (HEV) is primarily a waterborne virus that is transmitted by the fecal-oral route. (cdc.gov)
- Most people (up to 80%) infected with Hepatitis C virus do not have any symptoms in the beginning. (medicinenet.com)
- Hepatitis C virus is curable. (medicinenet.com)
- Researchers determined the structure of key hepatitis C virus proteins bound to three neutralizing antibodies. (nih.gov)
- Effective vaccines against the Hepatitis C virus have proven elusive, in part because of the difficulty of deciphering the structures on its surface. (nih.gov)
- This long sought-after structural information on hepatitis C virus puts a wealth of previous observations into a structural context and paves the way for rational vaccine design against this incredibly difficult target," Ward says. (nih.gov)
- Structure of the hepatitis C virus E1E2 glycoprotein complex. (nih.gov)
- Hepatitis B is caused by the hepatitis B virus. (medlineplus.gov)
- If you have ever had hepatitis B, the virus may become active again, or reactivated, later in life. (medlineplus.gov)
- If you think you have been in contact with the hepatitis B virus, see your health care provider right away. (medlineplus.gov)
- You need to get the vaccine and the HBIG (if needed) as soon as possible after coming into contact with the virus. (medlineplus.gov)
- Doctors treat hepatitis C with antiviral medicines that attack the virus and can cure the disease in most cases. (nih.gov)
- The hepatitis B virus vaccine is hypothesized to stimulate the immune system and trigger lichen planus eruptions in a nonspecific manner. (medscape.com)
- 2. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. (nih.gov)
- 5. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus. (nih.gov)
- 9. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. (nih.gov)
- 10. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. (nih.gov)
- 11. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. (nih.gov)
- 12. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. (nih.gov)
- 13. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. (nih.gov)
- 14. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. (nih.gov)
- 16. Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells. (nih.gov)
- Any vaccine raised against any virus or viral derivative that causes hepatitis. (nih.gov)
- Viral hepatitis is the term that describes inflammation of the liver that is caused by a virus. (cdc.gov)
- Hepatitis A is usually spread when a person ingests the virus from contact with objects, food, or drinks contaminated by solid waste from an infected person. (cdc.gov)
- The hepatitis B virus can be passed from an infected woman to her baby at birth, if her baby does not receive the hepatitis B vaccine. (cdc.gov)
- However, widespread screening of the blood supply in the United States began in 1990.The hepatitis C virus was virtually eliminated from the blood supply by 1992. (cdc.gov)
- 1998. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. (nationalacademies.org)
- World Health Organization (WHO) statistics reported 240 million people contaminated with hepatitis B virus (HBV) in 2016 with HBsAg-positive test for at least 6 months [ 2 ]. (biomedcentral.com)
- The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. (mdpi.com)
- Despite over 350 million people living with hepatitis B and C virus globally, and 3 persons dying every minute, much-needed efforts are yet to be on-track to end viral hepatitis in next 108 months (by 2030) as promised by heads of all countries in UN General Assembly (by adopting the Sustainable Development Goals). (modernghana.com)
- Globally, 296 million people are estimated to be infected with Hepatitis B Virus (HBV), and 58 million with Hepatitis C Virus (HCV). (modernghana.com)
- The use of nucleoside analogues against the agents of viral hepatitis is inherently problematic for many reasons including active hepatic nucleoside catabolism, probable absence of virus-specific activating enzymes, competition from endogenous nucleotides synthesised de novo or derived from RNA turnover, and factors related to mitochondrial toxicity. (edu.au)
- In the study, hepatitis B virus-naïve older adults received three vaccines, including one against HBV. (case.edu)
- Three of the 5 are viral vector vaccines, which use a partly disabled different virus to deliver coronavirus genes into cells, to make the surface proteins that provoke the immune response. (melvinkonner.com)
- Hepatitis A is viral disease of the liver caused by the hepatitis A virus (HAV). (nvic.org)
- The hepatitis A virus is very stable and can remain present for several months in most environments. (nvic.org)
- Symptoms of hepatitis A generally appear between two and seven weeks following exposure to the virus and infected individuals can spread the virus to others for up to two weeks before showing symptoms. (nvic.org)
Antigen3
- Australia antigen and hepatitis in renal units. (nih.gov)
- Informed by HIV self-testing success and community-wide acceptance and uptake of COVID-19 (rapid antigen tests - RATs) self-testing, there is a growing momentum internationally and in Australia behind self-testing for hepatitis C as part of a broader suite of testing approaches and strategies. (hepatitisaustralia.com)
- Hepatitis C RNA or antigen reflex testing implemented? (catie.ca)
Symptoms of hepatitis2
- In most people, what are symptoms of hepatitis C when initially infected? (medicinenet.com)
- What are the symptoms of hepatitis B? (medlineplus.gov)
Million people are infected with hepatitis1
- More than 400 million people are infected with hepatitis B or C worldwide. (gatewaygazette.ca)
CDC's2
- The CDC's 2010 professional judgment (PJ) budget recommended $90.8 million each year from FY2011-FY2013, $170.3 million annually from FY2014-FY2017, and $306.3 million annually from FY2018-FY2020 for DVH in order to comprehensively address the viral hepatitis epidemic. (hepb.org)
- Our recommendation of $47.8 million is in line with the needs determined by the PJ and the goals of the Viral Hepatitis Action Plan , but pales in comparison to the CDC's PJ. (hepb.org)
Effective vaccine2
- Hepatitis A is easily prevented with a safe and effective vaccine, which is believed to have caused the dramatic decline in new cases in recent years. (cdc.gov)
- This principle has yielded an effective vaccine for Ebola and an ineffective one for HIV. (melvinkonner.com)
Dose6
- Hepatitis A vaccine at the age-appropriate dose Table 1 is preferred for persons who plan to travel repeatedly to or reside for long periods in these high-risk areas. (cdc.gov)
- After receiving the initial dose of hepatitis A vaccine, persons are considered to be protected by 4 weeks. (cdc.gov)
- For persons who will travel to high-risk areas less than 4 weeks after the initial vaccine dose, IG (0.02 mL per kg of body weight) should be administered simultaneously with the first dose of vaccine but at different injection sites. (cdc.gov)
- Persons who are allergic to a vaccine component or otherwise elect not to receive vaccine should receive a single dose of IG (0.02 mL per kg of body weight), which provides effective protection against hepatitis A for up to 3 months. (cdc.gov)
- Participants received the plasma-derived hepatitis B vaccine by the standard schedule at 0, 1 and 6 months, and serum samples were collected at 3, 8, 12 and 24 months after the first dose. (nih.gov)
- Received live attenuated vaccines within 15 weeks before the first dose. (nih.gov)
Responses3
- Transcriptome analyses indicated that MAVS deficiency negatively affected the induction of early anti-viral responses, which resulted in significantly increased TBEV replication. (stanford.edu)
- The researchers found that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlated with stronger responses to the hepatitis B vaccine. (case.edu)
- In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlated with weaker responses to this vaccine. (case.edu)
Havrix1
- 2005). Prevention of hepatitis A by Havrix: a review . (nih.gov)
Infections3
- However, if precautions are not followed then transmission of hepatitis C and other infections may be possible. (medicinenet.com)
- Hepatitis C is one of the most common blood-borne infections in the United States. (nih.gov)
- Considering the importance of HB and HC, the present study aimed to estimate the prevalence of these viral infections among the PERSIAN Guilan cohort study (PGCS) participants. (biomedcentral.com)
Immunological1
- To characterize the biochemical and immunological properties of an experimental ISCOMS vaccine prepared from a novel therapeutic polypeptide based on T cell epitopes of HBsAg, and a heptatis B-ISCOMS was prepared and investigated. (wjgnet.com)
World Health Organ3
- The World Health Organization estimates 325 million people worldwide are living with chronic hepatitis B or chronic hepatitis C. In 2015, 1.34 million died from viral hepatitis , a number that is almost equal to the number of deaths caused by tuberculosis and HIV combined. (cdc.gov)
- According to the World Health Organization, an estimated 240 million people are chronically infected with hepatitis B and more than 780,000 people die every year due to complications of hepatitis B, including cirrhosis and liver cancer. (case.edu)
- This is an update on the 2021 report and provides an analysis of each province and territory's progress toward eliminating viral hepatitis as a public health threat by 2030, a goal set by the World Health Organization (WHO). (catie.ca)
ABCs1
- Where to go for the ABCs of viral hepatitis prevention? (cdc.gov)
Treatments for hepatitis1
- What are the treatments for hepatitis B? (medlineplus.gov)
Vaccinations1
- There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine. (case.edu)
Seroprevalence1
- No clear trends over time were observed in the seroprevalence of HEV, and HIV status was not associated with hepatitis seroprevalence. (cdc.gov)
Tuberculosis2
- Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis: By Mark Harrington, Bob Huff, and Richard Jefferys. (treatmentactiongroup.org)
- Viral hepatitis is an essential part of the #HealthForAll agenda", said Dr Tara Singh Bam, Asia Pacific Director of the International Union Against Tuberculosis and Lung Disease (The Union), and Board Director of Asia Pacific Cities Alliance for Health and Development (APCAT) in Singapore. (modernghana.com)
Cure for hepatitis1
- With a cure for hepatitis C and a vaccine for hepatitis B, this is an ambitious yet realistic goal. (catie.ca)
Prevention of hepatitis1
- The complete ACIP recommendations for the prevention of hepatitis A will be published. (cdc.gov)
Alcoholic hepatitis4
- People who drink a lot over long periods of time are at risk for alcoholic hepatitis. (nih.gov)
- People who have alcoholic hepatitis need to stop drinking. (nih.gov)
- For example, not drinking too much alcohol can prevent alcoholic hepatitis. (nih.gov)
- Similarly, drugs such as corticosteroids are used in treatment of alcoholic hepatitis and immunosuppressants are administered to patients with a transplanted liver. (alliedmarketresearch.com)
Types of hepatitis2
Risk for hepatitis2
- Who is at risk for hepatitis B? (medlineplus.gov)
- There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. (nih.gov)
Problems can hepatitis1
- What other problems can hepatitis B cause? (medlineplus.gov)
Medicines1
- Following three big days of inspiring presentations and reconnecting with many in the sector, Hepatitis Australia and the Australasian Society for HIV, Viral Hepatitis & Sexual Health Medicines (ASHM) launched the VH2022 Action Plan. (hepatitisaustralia.com)
Complications3
- If you have chronic hepatitis B, you may not have symptoms until complications develop. (medlineplus.gov)
- Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer . (nih.gov)
- Early diagnosis and treatment of chronic hepatitis may prevent these complications. (nih.gov)
Treat hepatitis1
- All these premature deaths are untimely and so preventable, because we have prevention tools, as well as good tests and drugs that can treat hepatitis B and C, and hepatitis C can be cured. (modernghana.com)
Autoimmune1
- Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. (nih.gov)
Infants1
- As a result, the hepatitis B vaccine is recommended for all infants at birth. (cdc.gov)
Viruses5
- There is not currently a vaccine available for Hepatitis C. There are vaccines for Hepatitis A and Hepatitis B, which are different viruses that can also affect the liver. (medicinenet.com)
- It is caused by one of several viruses -- hepatitis viruses A , B , C , D, and E. In the United States, A, B, and C are the most common. (nih.gov)
- The most common types of viral hepatitis are A, B and C. These three viruses affect millions of people worldwide, causing both short-term illness and long-term liver disease. (cdc.gov)
- The real-time PCR assay was employed to quantify the gene copies of hepatitis B and C viruses. (biomedcentral.com)
- Hepatitis B and C are the most common blood borne viruses in Australia but testing for them is not part of normal blood tests-you generally have to ask your doctor. (hepatitisaustralia.com)
20161
- Cleveland, OH - January 20, 2016 - Physicians have known for years that patients respond differently to vaccines as they age. (case.edu)
Inject drugs1
- Today, most people become infected with hepatitis C by sharing needles, syringes, or any other equipment to inject drugs. (cdc.gov)
Chemotherapy1
- Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. (edu.au)
19951
- The discovery and development of hepatitis A vaccines were landmark moments for public health, providing nearly 100 percent of adults with protective levels of antibodies, and contributing to the decline of hepatitis A rates in the U.S. by 92 percent since 1995 Hepatitis A FAQs for Health Professionals . (nih.gov)
Africa1
- Hepatitis B is common in many parts of the world, including Asia, the Pacific Islands and Africa. (cdc.gov)
Liver disease1
- Hepatitis C is a leading cause of long-term liver disease and liver cancer. (nih.gov)
Cirrhosis2
Inflammation of the liver1
- Hepatitis is inflammation of the liver . (medlineplus.gov)
Therapeutics1
- Most recently, both the NIH Director's Award for outstanding efforts leading to successful development of Covid vaccines and therapeutics and a presidential commendation for Covid-19 vaccine development, Operation Warp Speed. (nih.gov)
Warp Speed1
- It is not clear what criteria were used to choose those 5, but it is likely that the name "Warp Speed" will increase the number of vaccine refusers. (melvinkonner.com)
Living with chronic1
- There are about ___________ Americans living with chronic hepatitis C. (medicinenet.com)
Treatment5
- Some people with chronic hepatitis B will need treatment. (medlineplus.gov)
- However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C restrict the market growth. (alliedmarketresearch.com)
- Health+Law is a research partnership to identify and eliminate legal barriers to testing and treatment for people living with Hepatitis B or HIV in Australia. (hepatitisaustralia.com)
- The Motivate C project, led by the University of Sydney, is studying whether the offer of a cash incentive will encourage people to take up hepatitis C treatment in primary care. (hepatitisaustralia.com)
- Viral hepatitis affects a number of populations that have been historically marginalized by mainstream healthcare, creating hurdles to equitable prevention, testing and treatment services. (catie.ca)